Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 measures :

All OCTO Staff are now working remotely, for current information or queries about any of our trials please contact the trial team on their trial email address.

Contact information can be found at the top of each trial listing.


The portfolio includes a range of projects from first in human drug trials through to large Phase III clinical studies. Studies assess interventions including radiotherapy, drug combinations and novel imaging techniques.

Our current portfolio is divided into 3 categories:
  • Early phase.
  • Radiotherapy and Imaging.
  • Data Rich Trials.

Active Clinical Trials

 Prospective Clinical Trials

In Follow-up



  • ATOMPre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma.
  • 6MP: A Phase II Clinical trial in patients with known BRCA Defective Tumours.
  • ART: Anal squamous cell carcinoma: Investigation of functional imaging during Chemoradiotherapy (CRT)
  • AspECT: A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.
  • BKM120: A CR-UK phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy.
  • CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies
  • CHOP-OR: Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome. 
  • COGRandomised phase III trial of gefitinib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy.
  • CYTOFLOC: Evaluation of a Non‐Endoscopic Immunocytological Device (Cytosponge™) for post chemo‐radiotherapy surveillance in patients with oesophageal cancer – a feasibility study
  • DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring: A Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients with Metastatic Colorectal or Metastatic Breast Cancer.
  • DEBIOC: A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma
  • DOC-MEK: A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.  To determine the efficacy and tolerability of the combination of the selective MEK inhibitor AZD6244 with docetazel in patients with wild-type BRAF metastatic melanoma.
  • EnROL: Conventional versus laparoscopic surgery for colorectal cancer within an enhanced programme.
  • FOXFIRE: An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.
  • FRONTIER: An open-labelled study to characterise Fluciclovine (18F) uptake measured by positron emission tomography in breast cancer
  • LINES: Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma
  • MEMOS:
  • Mercuric: A Sequential Phase I study of MEK 1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor PF-02341066 in Patients with RAS Mutant and RAS Wild Type (with aberrant c-MET) Colorectal Cancer
  • NEOPANC-01: A phase 0, pre-operative, window-of-opportunity study to assess gene expression in patients with resectable pancreatic cancer 
  • Mobile Phone Project: Using GPRS mobile phone technology for managing symptoms associated with chemotherapy for colon cancer
  • OXO-PCR-01: A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy
  • PACMEL: A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
  • PEMBLA: A parallel group, open-label, multi-centre, randomised, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab. 
  • QUASAR 2: A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer.
  • RADVAN: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases.
  • RHYTHM-1: Modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer
  • SCOT: Short Course Oncology Treatment - A study of adjuvant chemotherapy in colorectal cancer by the  CACTUS and OCTO groups.
  • SONATINA: A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.
  • SPARC: Stereotactic Body Radiotherapy (SBRT) pre-operatively for pancreatic cancer: A Phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer.
  • TARDOX: A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours.
  • VICTOR: Post-treatment stage of a Phase III, randomised, double blind, placebo-controlled study of rofecoxib (VIOXX®) in colorectal cancer patients following potentially curative therapy.
  • WBRT: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised Phase III trial. 

On this page